Distinguished in Myelodysplastic Syndrome (MDS)

Dr. Rizwan Romee

Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Stem Cell Transplantation Program
450 Brookline Avenue, 
Boston, MA 
Clinical Trials:Currently Recruiting for 2 Trials
Distinguished in Myelodysplastic Syndrome (MDS)
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Stem Cell Transplantation Program
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rizwan Romee is an Oncologist in Boston, Massachusetts. Dr. Romee is rated as a Distinguished provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 134 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 12 articles and participated in 7 clinical trials in the study of Myelodysplastic Syndrome (MDS).

Specialties
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Hematology
Fellowships
Washington University, 2011 - 2012
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Dana-Farber Cancer Institute, Stem Cell Transplantation Program
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-4942

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Enrollment Status: Recruiting
Publish Date: January 02, 2026
Intervention Type: Drug, Biological
Study Drugs: CIML NK, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Enrollment Status: Recruiting
Publish Date: March 13, 2025
Intervention Type: Procedure
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: January 05, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2025
Intervention Type: Procedure, Drug
Study Drugs: Tacrolimus, Mycophenolate mofetil, G-CSF, ALT-803
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Procedure, Drug, Device
Study Phase: Phase 2
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Adults
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug
Study Drug: CIML NK Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS
Enrollment Status: Terminated
Publish Date: January 17, 2024
Intervention Type: Procedure, Biological, Drug
Study Drugs: Fludarabine, Cyclophosphamide, ALT-803, Cytokine-Induced Natural Killer T Cells, IL-2
Study Phase: Phase 1/Phase 2
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Genetic, Other
Study Phase: Phase 3
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 20, 2020
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: August 12, 2020
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Procedure, Drug
Study Phase: Phase 1/Phase 2
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 05, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 1
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: November 26, 2019
Intervention Type: Procedure, Drug
Study Phase: Phase 2
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 16, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence
Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence
Enrollment Status: Withdrawn
Publish Date: November 07, 2018
Intervention Type: Procedure, Other
Study Phase: Phase 1
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML
Enrollment Status: Terminated
Publish Date: October 12, 2018
Intervention Type: Radiation, Drug, Procedure
Study Phase: Phase 1
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: January 08, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1
A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes
Enrollment Status: Withdrawn
Publish Date: May 08, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 18 Less Clinical Trials

133 Total Publications

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.
Journal: Blood advances
Published: August 19, 2025
View All 133 Publications
Similar Doctors
Elite in Myelodysplastic Syndrome (MDS)
Dr. Andrew M. Brunner
Hematology Oncology | Hematology | Oncology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Andrew M. Brunner
Hematology Oncology | Hematology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Brunner is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Brunner is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Brunner is currently accepting new patients.

Richard M. Stone
Elite in Myelodysplastic Syndrome (MDS)
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Richard M. Stone
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Adult Leukemia Program

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-2214
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Stone is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Corey S. Cutler
Elite in Myelodysplastic Syndrome (MDS)
Dr. Corey S. Cutler
Hematology Oncology | Hematology | Transplant Surgery
Elite in Myelodysplastic Syndrome (MDS)
Dr. Corey S. Cutler
Hematology Oncology | Hematology | Transplant Surgery

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Corey Cutler is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Cutler is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Graft. Dr. Cutler is currently accepting new patients.

VIEW MORE MYELODYSPLASTIC SYNDROME (MDS) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Romee's expertise for a condition
ConditionClose
  • Elite
  • Acute Myeloid Leukemia (AML)
    Dr. Romee is
    Elite
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Romee is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Bone Marrow Transplant
    Dr. Romee is
    Distinguished
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Graft Versus Host Disease (GvHD)
    Dr. Romee is
    Distinguished
    . Learn about Graft Versus Host Disease (GvHD).
    See more Graft Versus Host Disease (GvHD) experts
  • Leukemia
    Dr. Romee is
    Distinguished
    . Learn about Leukemia.
    See more Leukemia experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Romee is
    Distinguished
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Myelofibrosis
    Dr. Romee is
    Distinguished
    . Learn about Myelofibrosis.
    See more Myelofibrosis experts
  • Advanced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Romee is
    Advanced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Romee is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Childhood Acute Myeloid Leukemia
    Dr. Romee is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Chronic Graft Versus Host Disease (cGvHD)
    Dr. Romee is
    Advanced
    . Learn about Chronic Graft Versus Host Disease (cGvHD).
    See more Chronic Graft Versus Host Disease (cGvHD) experts
  • Chronic Myelomonocytic Leukemia (CMML)
    Dr. Romee is
    Advanced
    . Learn about Chronic Myelomonocytic Leukemia (CMML).
    See more Chronic Myelomonocytic Leukemia (CMML) experts
  • Multiple Myeloma
    Dr. Romee is
    Advanced
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Experienced
  • Acute Erythroid Leukemia (AEL)
    Dr. Romee is
    Experienced
    . Learn about Acute Erythroid Leukemia (AEL).
    See more Acute Erythroid Leukemia (AEL) experts
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Romee is
    Experienced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Acute Promyelocytic Leukemia
    Dr. Romee is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Adult T-Cell Leukemia
    Dr. Romee is
    Experienced
    . Learn about Adult T-Cell Leukemia.
    See more Adult T-Cell Leukemia experts
  • Agranulocytosis
    Dr. Romee is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Aplastic Anemia
    Dr. Romee is
    Experienced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.